News & Updates

Patterns of thyroid-stimulating hormone (TSH) test show no substantial difference between type 2 diabetes patients treated with GLP-1 RAs and those who received SGLT-2 inhibitors, a study has found.

Perfluoroalkyl and polyfluoroalkyl substances (PFAS), also called “forever chemicals,” are normally detected in healthy girls, according to a study. Specifically, perfluorobutanesulfonic acid (PFBS) shows a positive association with estrone-3-glucuronide (E1G) levels, indicating potential ovarian effects.

A novel prescription delivery programme (PDP) appears to significantly reduce glycated haemoglobin levels (HbA1c) in patients with diabetes mellitus (DM), suggests a study.

Exercise interventions improve cardiometabolic health in people with metabolic syndrome, but achieving these benefits may depend on weight loss, as shown in a study.

In patients with metabolic dysfunction-associated steatotic liver disease or steatohepatitis, treatment with the novel glucagon and GLP-1 receptor dual agonist DD01 is associated with rapid reductions in liver fat, according to a phase II study.

In women with obesity who are scheduled to undergo endometrial cancer surgery, a preoperative weight loss intervention is feasible, helping reduce weight and the incidence of postoperative complications, according to a study.

In individuals with overweight or obesity, treatment with a glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to reduce binge eating severity and associated behaviours, including loss of control eating and disinhibited eating, according to a meta-analysis.

For adult patients with type 2 diabetes who are recovering from dialysis-requiring acute kidney injury (AKI-D), initiating sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy within 30 days of discharge is associated with fewer adverse kidney events compared with later initiation, as shown in a retrospective study.